Form 4: Rigel Pharmaceuticals EVP & CFO Reports Stock Option Grants After Performance Metrics Met
SEC Form 4 Filing
Dean L. Schorno, EVP & CFO of Rigel Pharmaceuticals, reports the acquisition of stock options after performance-based conditions were satisfied on March 17, 2025.
Summary
- Dean L. Schorno, the EVP & Chief Financial Officer of Rigel Pharmaceuticals, filed a Form 4 on March 19, 2025.
- The form reports the acquisition of stock options due to the satisfaction of performance-based conditions.
- Schorno was granted options to purchase 5,625 shares at an exercise price of $35.40 and 7,850 shares at an exercise price of $12.70 on March 17, 2025.
- These options were initially granted on January 27, 2021, and January 23, 2024, respectively, but were not reportable until the performance metrics were met.
- The options are exercisable immediately and expire on January 27, 2031, and January 23, 2034, respectively.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The satisfaction of performance metrics is a positive indicator, and the stock option grants align executive interests with shareholder value. However, the document is simply a regulatory filing and doesn't provide broader insights into the company's overall performance.
Positives
- The satisfaction of performance metrics suggests positive progress within Rigel Pharmaceuticals.
- The granting of stock options aligns the executive's interests with those of the shareholders.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with company performance and shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their executives.
- The vesting schedules and performance-based conditions are typical mechanisms to ensure long-term alignment and achievement of strategic goals.
Stakeholder Impact
- Shareholders may view the satisfaction of performance metrics and the granting of stock options as a positive sign of company progress.
- Employees may be motivated by the company's achievement of performance goals.
Key Dates
| Date | Description |
|---|---|
| January 27, 2021 | Initial grant date of stock option for 5,625 shares (subject to reverse stock split). |
| January 23, 2024 | Initial grant date of stock option for 7,850 shares (subject to reverse stock split). |
| June 27, 2024 | Effective date of one-for-ten reverse stock split. |
| March 17, 2025 | Date performance metrics were met, triggering the reporting requirement for the stock option grants. |
| March 19, 2025 | Date of Form 4 filing. |
| January 27, 2031 | Expiration date of stock option for 5,625 shares. |
| January 23, 2034 | Expiration date of stock option for 7,850 shares. |
Keywords
Stock Options, Form 4, Rigel Pharmaceuticals, Executive Compensation, Dean L. Schorno, Performance Metrics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.